Geron Corporation (GERN) — RQD Stock Rating Cockpit

The per-the Roarable RQD rating assigns a score of 29 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

• Fundamental Cash Engine: 6 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of -20.2% and an FCF yield of -18.27%. Negative returns on invested capital and negative free-cash-flow yield indicate the business is consuming cash rather than generating it relative to its capital base.
• Whale 13F Flow: 4 / 20. Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning. The low score indicates that institutional flow signals are weak in the source data.
• Insider Conviction: 3 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. This is the lowest pillar score, indicating insider and disclosed-trade signals are not supportive in the source data.
• Macro Regime Fit: 6 / 20. Per the Roarable RQD rating, this pillar reflects beta of 1.0 and sector sensitivity. A beta of 1.0 implies market-level sensitivity, and the score reflects limited regime-fit support.
• Forensic Balance Sheet: 10 / 20. Per the Roarable RQD rating, this pillar reflects Altman Z 2.5, Piotroski F 3/9, and Debt/Equity 0.53. This is the strongest pillar, but still only half of its maximum.

For a prospective investor evaluating the stock today, the rating points to a weak fundamental cash profile, weak insider and institutional signals, and a balance sheet that is the least-weak area rather than a strength. The price of 0.95 sits near the lower portion of the 52-week range, which is a factual observation and not an indication of value. Upside drivers are not evident in the rating's pillars; the cited evidence is predominantly downside-oriented.

Per the SEC financials, the company reported operating and net losses across all three periods, with the FY 2025 net loss narrowing to $-83.5M from $-174.6M in FY 2024. Per the market data, gross, operating, and net margins are each 0%, and ROIC is -20.2%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 3/9, and Debt/Equity is 0.53; per the financials, debt was $119.5M against cash of $77.6M in FY 2025.

The news wire contains six items, all tagged to GERN. The most prominent headline is "Geron stock tumbles after halting Phase 3 trial" (Yahoo Finance), flagged YELLOW under the MARKET WIRE label. A second headline, "Geron stock drops after halting Rytelo trial (GERN:NASDAQ)" (Seeking Alpha), is flagged RED under the RISK WATCH label. The remaining four items (ChartMill, StockInvest.us, Nasdaq, TradingView) are flagged YELLOW under MARKET WIRE and are generic in summary. Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links and no proprietary signals.

• What specific Phase 3 trial was halted, and what is the disclosed reason and timeline for resumption, according to primary filings not included here?
• Given zero reported revenue and recurring operating losses, what is the company's funding runway relative to its $77.6M cash position in FY 2025?
• What drove the decline in net loss from $-174.6M in FY 2024 to $-83.5M in FY 2025, and was it operational or non-recurring?
• Are any analyst price targets, consensus ratings, or institutional 13F holdings available to compare with the RQD signals?
• What is the source of the forward P/E, EPS, and EV/EBITDA gaps, and can valuation be assessed with the missing earnings figures?